oral FGFR1/2/3 kinase inhibitor
approved in oncology, 13.5 mg QD (14d+, 7d-)
from focused screen of ~20k cmpds and SBDD
Journal of Medicinal Chemistry
Incyte Corporation, Wilmington, US
pemigatinib
The Incyte FGFR1/2/3 kinase inhibitor, pemigatinib, is an oral kinase inhibitor that obtained an FDA accelerated approval in 2020 for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with…